CN105026362B - 双环化合物 - Google Patents
双环化合物 Download PDFInfo
- Publication number
- CN105026362B CN105026362B CN201480009497.1A CN201480009497A CN105026362B CN 105026362 B CN105026362 B CN 105026362B CN 201480009497 A CN201480009497 A CN 201480009497A CN 105026362 B CN105026362 B CN 105026362B
- Authority
- CN
- China
- Prior art keywords
- compound
- salt
- compounds
- mmol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1CC(C2)C2*C1 Chemical compound *C1CC(C2)C2*C1 0.000 description 5
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 3
- JAPMJSVZDUYFKL-UHFFFAOYSA-N C1C2C1CCC2 Chemical compound C1C2C1CCC2 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 2
- HIVPKYMYZGCUOY-DENIHFKCSA-N CCCCCOc(cc1)cc2c1cc([C@H](CC1)C[C@]1(CO1)NC1=O)cc2 Chemical compound CCCCCOc(cc1)cc2c1cc([C@H](CC1)C[C@]1(CO1)NC1=O)cc2 HIVPKYMYZGCUOY-DENIHFKCSA-N 0.000 description 1
- DXRSYLNLGBXYNJ-ZWNOBZJWSA-N COC([C@@](CC1)(C[C@@H]1c(cc1)ccc1Br)N)=O Chemical compound COC([C@@](CC1)(C[C@@H]1c(cc1)ccc1Br)N)=O DXRSYLNLGBXYNJ-ZWNOBZJWSA-N 0.000 description 1
- QZNVDUNLSBAHST-UHFFFAOYSA-N O=C(CC1)CC11C2=CC=C(C(F)(F)F)C=CC12 Chemical compound O=C(CC1)CC11C2=CC=C(C(F)(F)F)C=CC12 QZNVDUNLSBAHST-UHFFFAOYSA-N 0.000 description 1
- MYYWJTMDTXMNPP-XKKYWNAESA-N O=C1N(CC(CC2)C[C@@H]2C2C=CC(Br)=CC2)C2O[C@@H]2N1 Chemical compound O=C1N(CC(CC2)C[C@@H]2C2C=CC(Br)=CC2)C2O[C@@H]2N1 MYYWJTMDTXMNPP-XKKYWNAESA-N 0.000 description 1
- GKJWLMMNYJYRMH-RHSMWYFYSA-N O=C1OC[C@@](CC2)(C[C@@H]2c2ccc(CC(CC3)=O)c3c2)N1 Chemical compound O=C1OC[C@@](CC2)(C[C@@H]2c2ccc(CC(CC3)=O)c3c2)N1 GKJWLMMNYJYRMH-RHSMWYFYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
- C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
- C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
- C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767531P | 2013-02-21 | 2013-02-21 | |
| US61/767,531 | 2013-02-21 | ||
| PCT/US2014/017534 WO2014130752A2 (en) | 2013-02-21 | 2014-02-21 | Bicyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105026362A CN105026362A (zh) | 2015-11-04 |
| CN105026362B true CN105026362B (zh) | 2017-07-14 |
Family
ID=50272738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480009497.1A Active CN105026362B (zh) | 2013-02-21 | 2014-02-21 | 双环化合物 |
Country Status (34)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6617702B2 (ja) | 2013-07-15 | 2019-12-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｆｔｙ７２０のアザサイクリック拘束アナログ |
| TWI689487B (zh) * | 2014-08-20 | 2020-04-01 | 美商必治妥美雅史谷比公司 | 經取代雙環化合物 |
| JP6853539B2 (ja) * | 2015-09-24 | 2021-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法 |
| JP7029445B2 (ja) | 2016-09-02 | 2022-03-03 | ブリストル－マイヤーズ スクイブ カンパニー | 置換された三環式ヘテロ環化合物 |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| WO2021062168A1 (en) * | 2019-09-25 | 2021-04-01 | The Regents Of The University Of California | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
| CN102361869A (zh) * | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
| WO2012150234A1 (en) * | 2011-05-04 | 2012-11-08 | Glaxosmithkline Llc | Dihydroquinoline derivatives as bromodomain inhibitors |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| DE60330047D1 (en) | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
| AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| EP1482895A4 (en) | 2002-03-01 | 2005-04-27 | Merck & Co Inc | AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS |
| AU2003276043A1 (en) | 2002-06-17 | 2003-12-31 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| EP2644195A1 (en) | 2003-05-19 | 2013-10-02 | Irm Llc | Immunosuppressant Compounds and Compositions |
| JP4773972B2 (ja) | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸 |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| BRPI0607435A2 (pt) | 2005-02-14 | 2010-04-06 | Univ Virginia | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, e, uso de um composto |
| CA2598365A1 (en) | 2005-02-18 | 2006-11-16 | Innodia Inc. | Analogs of 4-hydroxyisoleucine and uses thereof |
| AU2006222563A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| NZ562561A (en) | 2005-03-23 | 2010-11-26 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists |
| TW200642683A (en) | 2005-04-22 | 2006-12-16 | Sankyo Co | Heterocyclic compound |
| JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用 |
| US20090221547A1 (en) | 2005-08-23 | 2009-09-03 | Irm Llc | Immunosuppressant Compounds and Compositions |
| JP5432526B2 (ja) | 2006-01-06 | 2014-03-05 | サノビオン ファーマシューティカルズ インク | モノアミン再取り込み阻害剤としてのシクロアルキルアミン |
| EP1986623A2 (en) | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| EP2010524A2 (en) | 2006-03-21 | 2009-01-07 | Epix Delaware, Inc. | S1p receptor modulating compounds |
| AU2007229850A1 (en) | 2006-03-23 | 2007-10-04 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| CA2648303C (en) | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| US8288554B2 (en) | 2006-09-08 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyridin-3-yl derivatives as immunomodulating agents |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| EP2120575A4 (en) * | 2006-12-21 | 2011-04-27 | Abbott Lab | AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS |
| MX2009008255A (es) | 2007-02-02 | 2009-08-12 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos taar1. |
| MX2009009597A (es) | 2007-03-16 | 2009-09-16 | Actelion Pharmaceuticals Ltd | Derivados de amino-piridina como agonistas del receptor s1p1/edg1. |
| CA2696863C (en) | 2007-10-04 | 2016-10-18 | Anna Quattropani | Oxadiazole derivatives |
| BRPI0818804A2 (pt) | 2007-11-01 | 2015-04-22 | Actelion Pharmaceuticals Ltd | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| WO2009124022A1 (en) | 2008-04-01 | 2009-10-08 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| AU2009304596A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| CN102245602B (zh) | 2008-12-18 | 2014-09-10 | 默克雪兰诺有限公司 | 用于治疗多发性硬化症的与恶二唑稠合的杂环衍生物 |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| JP2012515789A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体 |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| CA2750125A1 (en) | 2009-02-10 | 2010-08-19 | Abbott Laboratories | Methods for preparing s1p receptor agonists and antagonists |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2493866A1 (en) | 2009-10-29 | 2012-09-05 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| CN102260178A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| ES2539256T3 (es) | 2010-07-20 | 2015-06-29 | Bristol-Myers Squibb Company | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos |
| JP5869579B2 (ja) | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 |
| WO2012061459A1 (en) | 2010-11-03 | 2012-05-10 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| EP2685971A2 (en) * | 2011-03-18 | 2014-01-22 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| JP5090580B1 (ja) | 2011-04-26 | 2012-12-05 | パナソニック株式会社 | 暖房システム及び暖房システム制御方法 |
| WO2012158550A2 (en) | 2011-05-13 | 2012-11-22 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| MX362346B (es) | 2012-07-27 | 2019-01-11 | Biogen Ma Inc | Compuestos que son agentes moduladores de s1p y/o agentes moduladores de autotaxina. |
-
2014
- 2014-02-20 TW TW103105719A patent/TWI613182B/zh not_active IP Right Cessation
- 2014-02-20 US US14/185,164 patent/US9115054B2/en active Active
- 2014-02-20 UY UY0001035338A patent/UY35338A/es unknown
- 2014-02-21 AU AU2014218883A patent/AU2014218883B2/en not_active Ceased
- 2014-02-21 HR HRP20170247TT patent/HRP20170247T1/hr unknown
- 2014-02-21 AR ARP140100554A patent/AR094851A1/es unknown
- 2014-02-21 DK DK14709822.2T patent/DK2958888T3/en active
- 2014-02-21 SM SM20170115T patent/SMT201700115T1/it unknown
- 2014-02-21 MA MA38425A patent/MA38425B1/fr unknown
- 2014-02-21 LT LTEP14709822.2T patent/LT2958888T/lt unknown
- 2014-02-21 KR KR1020157025410A patent/KR102242265B1/ko not_active Expired - Fee Related
- 2014-02-21 EA EA201591409A patent/EA025294B1/ru not_active IP Right Cessation
- 2014-02-21 RS RS20170188A patent/RS55703B1/sr unknown
- 2014-02-21 PE PE2015001795A patent/PE20151746A1/es active IP Right Grant
- 2014-02-21 MY MYPI2015702746A patent/MY173990A/en unknown
- 2014-02-21 SI SI201430106A patent/SI2958888T1/sl unknown
- 2014-02-21 HU HUE14709822A patent/HUE031626T2/en unknown
- 2014-02-21 CN CN201480009497.1A patent/CN105026362B/zh active Active
- 2014-02-21 SG SG11201506408TA patent/SG11201506408TA/en unknown
- 2014-02-21 EP EP14709822.2A patent/EP2958888B1/en active Active
- 2014-02-21 WO PCT/US2014/017534 patent/WO2014130752A2/en not_active Ceased
- 2014-02-21 ES ES14709822.2T patent/ES2613262T3/es active Active
- 2014-02-21 PL PL14709822T patent/PL2958888T3/pl unknown
- 2014-02-21 CA CA2902168A patent/CA2902168C/en not_active Expired - Fee Related
- 2014-02-21 MX MX2015010347A patent/MX2015010347A/es unknown
- 2014-02-21 JP JP2015558976A patent/JP6277210B2/ja not_active Expired - Fee Related
- 2014-02-21 BR BR112015019919A patent/BR112015019919A2/pt not_active Application Discontinuation
- 2014-02-21 PT PT147098222T patent/PT2958888T/pt unknown
-
2015
- 2015-07-14 US US14/798,498 patent/US9359286B2/en active Active
- 2015-08-14 PH PH12015501793A patent/PH12015501793B1/en unknown
- 2015-08-17 IL IL240613A patent/IL240613B/en active IP Right Grant
- 2015-08-18 TN TN2015000356A patent/TN2015000356A1/en unknown
- 2015-08-21 CL CL2015002358A patent/CL2015002358A1/es unknown
- 2015-09-18 ZA ZA2015/06965A patent/ZA201506965B/en unknown
-
2016
- 2016-05-06 US US15/148,222 patent/US9487481B2/en active Active
-
2017
- 2017-02-16 CY CY20171100216T patent/CY1118641T1/el unknown
- 2017-02-21 SM SM201700115T patent/SMT201700115B/it unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
| CN102361869A (zh) * | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
| WO2012150234A1 (en) * | 2011-05-04 | 2012-11-08 | Glaxosmithkline Llc | Dihydroquinoline derivatives as bromodomain inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105026362B (zh) | 双环化合物 | |
| US11701373B2 (en) | Substituted bicyclic compounds | |
| US11046646B2 (en) | Alkylphenyl compounds | |
| JP7029445B2 (ja) | 置換された三環式ヘテロ環化合物 | |
| HK1218111B (en) | Bicyclic compounds | |
| WO2025137366A2 (en) | Solid-state forms of stat3 inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |